Feedback plc
Bleepa-CareLocker contract extension with Queen Victoria Hospital
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that it has been awarded a nine-month, fixed-term contract extension of its contract for the Sussex Health and Care Partnership Integrated Care System ("Sussex ICS") development programme with Queen Victoria Hospital ("QVH") for Feedback's Bleepa-CareLocker Community Diagnostics Centre ("CDC") solution.
This paid extension, which follows the success of the Company's existing contract (details of which were announced by Feedback on 6 September 2022), follows the abandonment of the Trust's previous procurement process in March 2023 and will cover the period from 1 April 2023 until 31 December 2023 whilst QVH undertakes a new tender exercise under the Public Contracts Regulations 2015. A new tender process for the next phase of the CDC programme rollout is due to commence imminently.
QVH is expected to procure the relevant components of the CDC programme, including the digital pathway element, currently under contract with Feedback.
Dr Tom Oakley, CEO Feedback plc said: "Although QVH had expected to conclude its tender process by 31st March 2023, we have been informed by the Trust that the existing tender process is no longer progressing. We are pleased to be supporting QVH on an interim basis to ensure the continuity of ongoing patient care whist they undertake a further procurement exercise.
"The digital component of CDC delivery that Feedback provides is critical, and we continue to champion the QVH CDC programme to other NHS organisations through the continuation of this contract, and remain confident in the emerging opportunity that CDCs represent both for the Company and the wider NHS. While we continue to support QVH, the Company will actively explore opportunities to support the wider CDC capability throughout the NHS."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.
-Ends-
Enquiries:
Feedback plc Tom Oakley, CEO Anesh Patel, CFO | +44 (0) 20 3997 7634 |
| |
Panmure Gordon (UK) Limited (NOMAD and Broker) Emma Earl/Freddy Crossley (Corporate Finance) Rupert Dearden (Corporate Broking) | +44 (0)20 7886 2500 |
| |
Walbrook PR Ltd; | Tel: 020 7933 8780 or feedbackplc@walbrookpr.com |
Nick Rome/Joe Walker | 07748 325 236 or 07407 020 470 |
About Feedback
Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment.
Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.
The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.